Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon

Report: Global CV surgery device market to reach $2.4B by 2016

The global market for cardiovascular surgery devices is expected to reach $2.4 billion in 2016growing by a compound annual growth rate of 3 percent from the $2 billion market valuation in 2009, according to a report by GlobalData.

Thoratec narrows focus on LVADs through $55M sale of ITC

Thoratec, a developer of device-based mechanical circulatory support therapies for heart failure, has sold its International Technidyne Corporation (ITC) division to an affiliate of Warburg Pincus, pursuant to a definitive stock purchase agreement of approximately $55 million. ITC develops products for hemostasis management and point-of-care testing.

AJC: ACS patients better off in RCTs than registries

Differences exist in treatment, outcomes and baseline characteristics in acute coronary syndrome (ACS) patients who participated in clinical trials compared to those tracked in registries, according to the results of a study published online Oct. 8 in the American Journal of Cardiology (AJC).

Drug-coated balloons find niche where DES dare not go

Drug-coated balloon technology is being adopted in niche applications throughout Europe, and according to Millennium Research Group, the market will continue to grow as physicians increasingly use the technology in cases where other devices may not be suitable.

JACC: Gait speed predicts outcomes in elderly CABG patients

Gait speed, a marker of frailty, can be a useful marker to predict mortality and major morbidity in subsets of elderly patients undergoing cardiac surgery, according to a study published Nov. 9 in the Journal of the American College of Cardiology.

Pfizer recalls 38K bottles of Lipitor

Pfizer has announced that it intends to recall two additional lotsapproximately 38,000 bottlesof atorvastatin calcium (Lipitor) 40 mg tablets, distributed in the U.S.

Platelet Function Testing: Time to Get Personal

While clopidogrel is a successful antiplatelet drug for PCI patients, its ineffectiveness in certain patient subsets has recently been documented, spurring an FDA boxed warning. Testing patients platelet responsiveness or their genotype has shown success, but which tests are most effective and efficacious? Further compounding these cath lab choices, newer antiplatelet agents loom as potential game changers.

Medicines Co. skips into the black for Q3, partly due to Angiomax sales

The Medicines Company has pulled itself out of the red and posted a strong net income for the 2010 third quarter, compared with the same fiscal period in 2009.

Displaying 2329 - 2336 of 2712

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.